Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection.

Autor: Yilmaz IC; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Ipekoglu EM; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey., Bulbul A; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Turay N; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Yildirim M; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Evcili I; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Yilmaz NS; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey., Guvencli N; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey., Aydin Y; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey., Gungor B; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Saraydar B; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Bartan AG; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Ibibik B; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Bildik T; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Baydemir İ; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey., Sanli HA; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey., Kayaoglu B; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey., Ceylan Y; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Yildirim T; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Abras I; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Ayanoglu IC; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey., Cam SB; Hacettepe University Faculty of Medicine Department of Histology and Embryology, Ankara, Turkey., Ciftci Dede E; Hacettepe University Graduate School of Science and Engineering, Department of Bioengineering, Ankara, Turkey., Gizer M; Hacettepe University Graduate School of Health Sciences, Department of Stem Cell Sciences, Ankara, Turkey., Erganis O; Faculty of Veterinary Medicine, Selcuk University, Konya, Turkey., Sarac F; Pendik Veterinary Research and Control Institute, Istanbul, Turkey., Uzar S; Pendik Veterinary Research and Control Institute, Istanbul, Turkey., Enul H; Pendik Veterinary Research and Control Institute, Istanbul, Turkey., Adiay C; Pendik Veterinary Research and Control Institute, Istanbul, Turkey., Aykut G; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Polat H; Marmara Research Center, TUBITAK, Istanbul, Turkey., Yildirim IS; Marmara Research Center, TUBITAK, Istanbul, Turkey., Tekin S; Marmara Research Center, TUBITAK, Istanbul, Turkey., Korukluoglu G; Virology Laboratory, General Directorate of Public Health, Ankara, Turkey., Zeytin HE; Biotechnology Research Center, Nobel Pharma, Istanbul, Turkey., Korkusuz P; Hacettepe University Faculty of Medicine Department of Histology and Embryology, Ankara, Turkey., Gursel I; Molecular Biology and Genetics Department, Bilkent University, Ankara, Turkey., Gursel M; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Allergy [Allergy] 2022 Jan; Vol. 77 (1), pp. 258-270. Date of Electronic Publication: 2021 Sep 21.
DOI: 10.1111/all.15091
Abstrakt: Background: Vaccines that incorporate multiple SARS-CoV-2 antigens can further broaden the breadth of virus-specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS-CoV-2 VLP vaccine that incorporates the four structural proteins of SARS-CoV-2.
Methods: VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography, and characterized by tunable-resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine.
Results: Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS-CoV-2. Alum adsorbed, K3-CpG ODN-adjuvanted VLPs elicited high titer anti-S, anti-RBD, anti-N IgG, triggered multifunctional Th1-biased T-cell responses, reduced virus load, and prevented lung pathology upon live virus challenge in vaccinated animals.
Conclusion: These data suggest that VLPs expressing all four structural protein antigens of SARS-CoV-2 are immunogenic and can protect animals from developing COVID-19 infection following vaccination.
(© 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: